Pharmacological treatment options are available to customers with a BMI > 30kg/m2 (27kg/m2 if weight-related co-morbidities)

There are 3 options currently being provided through community pharmacy:

• Orlistat
• Mysimba (Naltrexone/Bupropion)
• Saxenda (Liraglutide)

N.B. These medical interventions are only licenced where the customer has made changes to their diet and lifestyle to support their weight loss journey

It is important for health providers to use BMI in conjunction with a clinical and behavioural assessment, in order to determine the most appropriate treatment option and if the need for referral is necessary.

Other factors to consider include:

Waist circumference

• Carrying too much fat around the middle is associated with an increased risk of developing heart disease and diabetes. Currently NICE recommends that waist circumference is used together with BMI to assess the health risks.
• Generally, men with a waist size of 94cm or more and women with a waist size of 80cm or more are more likely to develop obesity-related health problems.

Ethnicity
Your ethnic group can also affect your risk of some health conditions. For example, adults of Asian origin may have a higher risk of health problems at BMI levels above 25.

The next screens will explore the 3 forms of medical intervention available in pharmacy.